Miller Jessica E, Ahn Soo Hyun, Marks Ryan M, Monsanto Stephany P, Fazleabas Asgerally T, Koti Madhuri, Tayade Chandrakant
Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada.
Department of Obstetrics, Gynecology, and Reproductive Biology, Michigan State University, Grand Rapids, MI, United States.
Front Immunol. 2020 Feb 14;11:108. doi: 10.3389/fimmu.2020.00108. eCollection 2020.
Endometriosis is a debilitating gynecological disease characterized by the extrauterine presence of endometrial-like tissues located on the peritoneal membrane and organs of the pelvic cavity. Notably, dysfunctional immune activation in women with endometriosis could also contribute to the development of disease. In particular, alternatively activated (M2) peritoneal macrophages are shown to aid peritoneal lesion development by promoting remodeling of extracellular matrix and neovascularization of lesions. However, the stimuli responsible for polarizing M2 macrophages in endometriosis remain elusive. Interleukin-17A (IL-17A) can induce M2 macrophage polarization in other disease models and IL-17A is elevated in the plasma and endometriotic lesions of women with endometriosis. In this study, we investigated whether IL-17A could induce macrophage recruitment and M2 polarization, while promoting endometriotic lesion growth through enhanced vascularization. By utilizing a co-culture of macrophage-like THP-1 cells with an endometriotic epithelial cell line, our results suggest that IL-17A indirectly induces M2 markers CCL17 and CD206 by interacting with endometriotic epithelial cells. Further, in a syngeneic mouse model of endometriosis, IL-17A treatment increased macrophages in the peritoneum, which were also M2 in phenotype. However, IL-17A treatment did not augment proliferation or vascularization of the lesion in the study time frame. These findings suggest that IL-17A may be a stimulus inducing the pathogenic polarization of macrophages into the M2 phenotype by first acting on the endometriotic lesion itself.
子宫内膜异位症是一种使人衰弱的妇科疾病,其特征是在盆腔腹膜和器官上存在类似子宫内膜的组织。值得注意的是,子宫内膜异位症女性的免疫激活功能失调也可能导致疾病的发展。特别是,交替激活的(M2)腹膜巨噬细胞被证明通过促进细胞外基质重塑和病变新生血管形成来帮助腹膜病变发展。然而,导致子宫内膜异位症中M2巨噬细胞极化的刺激因素仍然不清楚。白细胞介素-17A(IL-17A)在其他疾病模型中可诱导M2巨噬细胞极化,并且IL-17A在子宫内膜异位症女性的血浆和异位内膜病变中升高。在本研究中,我们调查了IL-17A是否能诱导巨噬细胞募集和M2极化,同时通过增强血管生成促进异位内膜病变生长。通过将巨噬细胞样THP-1细胞与异位内膜上皮细胞系共培养,我们的结果表明IL-17A通过与异位内膜上皮细胞相互作用间接诱导M2标志物CCL17和CD206。此外,在同基因子宫内膜异位症小鼠模型中,IL-17A治疗增加了腹膜中的巨噬细胞,其表型也为M2。然而,在研究时间范围内,IL-17A治疗并未增加病变的增殖或血管生成。这些发现表明,IL-17A可能是一种刺激因素,首先作用于异位内膜病变本身,诱导巨噬细胞向M2表型的致病性极化。